Ketamine & Next Generation Therapies

Tuesday, August 13, 2013
Ketamine & Next Generation Therapies

Watch Video Recording:

Presented by 
Carlos A. Zarate, Jr., M.D.
Carlos A. Zarate, Jr., M.D.
National Institute of Mental Health

Chief, Experimental Therapeutics & Pathophysiology Branch and Section on the Neurobiology and Treatment of Mood Disorders

Scientific Council Member (Joined 2019)

2011 Bipolar Mood Disorders Award Prizewinner (Colvin Prize)

2005 Independent Investigator Grant

1996 Young Investigator Grant

 

Carlos A. Zarate, M.D., a NARSAD Independent Investigator Grantee (2005), has pioneered revolutionary studies that have led to novel treatments for mood disorders such as depression and bipolar disorder that begin working much faster than previous options. Dr. Zarate is Chief of Experimental Therapeutics of the Mood and Anxiety Disorders Program at the National Institute of Mental Health (NIMH), and Clinical Professor of Psychiatry and Behavioral Sciences at George Washington University. With a strong focus on the pathophysiology of severe mental illnesses, his goal is to develop better treatments particularly for patients living with depression, bipolar disorder and/or other mood disorders. His research into a drug called Ketamine has resulted in rapid-acting depression treatments that work within hours and last 3-5 days or more. Because of the speed at which this drug reacts within the body and the duration of its effects, it is possible that emergency room doctors may have a possible treatment for those suffering from depression and acute suicidality.

“For me it’s an exciting time to be a researcher. We didn’t have much of these technologies even a decade ago and now we have all these options and possibilities. And that will definitely, and it has, led to an increased understanding of what are the causes of the illness, maybe what are potentially promising targets to develop better treatments. These things we didn’t have in recent past.”

Dr. Zarate was recognized for this discovery and his career of work at the Brain & Behavior Research Foundation National Awards Dinner in New York City in October 2011 with the Bipolar Mood Disorder Outstanding Achievement Prize (renamed the Colvin Prize for Outstanding Achievement in Mood Disorders Research in 2012).

Moderated by 
Jeffrey Borenstein, M.D.
Brain & Behavior Research Foundation

President and CEO

 

Jeffrey Borenstein, M.D., serves as the President & CEO of the Brain & Behavior Research Foundation, the largest private funder of mental health research grants. Dr. Borenstein developed the Emmy-nominated public television program “Healthy Minds,” and serves as host and executive producer of the series. The program, broadcast nationwide, is available online, and focuses on topics in psychiatry in order to educate the public, reduce stigma and offer a message of hope. Dr. Borenstein also serves as Editor-in-Chief of Psychiatric News, the newspaper of the American Psychiatric Association.

Dr. Borenstein is a Fellow of the New York Academy of Medicine and serves as the Chair of the Section of Psychiatry at the Academy. He also has served as the President of the New York State Psychiatric Association. Dr. Borenstein earned his undergraduate degree at Harvard and his medical degree at New York University.